Rhabdomyosarcoma

8 trials 4 recruiting MedDRA PT
8 Registered trials
4 Recruiting
7 Unique sponsors
9 Unique IMPs
4 Commercial trials
Drug classes (ATC)
V Various (ATC V) 2
L Oncology (ATC L) 1
— ATC code not specified 5
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Monoclonal antibody (immune) 2 substances
Radiopharmaceutical 1 substance
Antibody-drug conjugate (ADC) 1 substance
CDK inhibitor 1 substance
RAF/BRAF inhibitor 1 substance
Phase III: 1 Phase II: 1 Phase I/II: 5 Phase I (Other): 1

Filter these 8 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 8 trials

Phase III

1 trial
  • Universitaet Muenster Academic
    TTF-NGR
    2024-516392-33-00 1 country 2021 n=126
    Recruiting

Phase II

1 trial
  • The University Of Birmingham Academic
    INDOCYANINE GREEN
    2024-514089-37-00 1 country n=30
    Pending

Phase I/II

5 trials
  • Glaxosmithkline Research & Development Limited Commercial
    COBOLIMAB; DOSTARLIMAB
    2024-511350-41-00 6 countries 2025 n=46
    Ended
  • Merck Sharp & Dohme LLC Commercial
    PATRITUMAB DERUXTECAN
    2024-518771-66-00 12 countries 2025 n=32
    Recruiting
  • Novartis Pharma AG Commercial
    RIBOCICLIB
    2024-512095-35-00 7 countries 2022 n=49
    Ended
  • Centre Oscar Lambret Academic
    IMP not specified
    2024-513470-22-00 1 country 2019 n=63
    Ended
  • The University Of Birmingham Academic
    REGORAFENIB
    2024-510579-40-00 16 countries 2020 n=1,185
    Recruiting

Phase I (Other)

1 trial
  • ITM Solucin GmbH Commercial
    L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; LUTETIUM (177LU) EDOTREOTIDE
    2024-512831-66-00 3 countries 2025 n=16 Orphan
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
The University Of Birmingham Academic 2 Phase II, Phase I/II 1
ITM Solucin GmbH Commercial 1 Phase I (Other) 1
Glaxosmithkline Research & Development Limited Commercial 1 Phase I/II 0
Merck Sharp & Dohme LLC Commercial 1 Phase I/II 1
Novartis Pharma AG Commercial 1 Phase I/II 0
Universitaet Muenster Academic 1 Phase III 1
Centre Oscar Lambret Academic 1 Phase I/II 0
New trials by year
2019
1
2020
1
2021
1
2022
1
2025
3
← All indication landscapes